Developer docs
API playgroundTry for free, no card

Search company profiles

RedShift BioAnalytics

Full company profile

uuid00026p6

Namestring
RedShift BioAnalytics
Legal namestring
RedShift BioAnalytics, Inc.
Websiteurl
redshiftbio.com
Company typeenum
Private
Founded yearint
2005
Descriptiontext

RedShift BioAnalytics, Inc. (operating as RedShiftBio) is a privately held, Delaware-incorporated analytical instrumentation company founded in 2005 and headquartered at 80 Central Street, Boxborough, Massachusetts. It develops and manufactures bioanalytical tools based on its proprietary Microfluidic Modulation Spectroscopy (MMS) platform, which pairs a tunable quantum cascade laser (at least ~1,000x more intense than conventional IR sources) with a microfluidic flow cell to enable real-time background subtraction and ultra-sensitive measurement of protein secondary structure across a 0.1 to >200 mg/mL concentration range with minimal buffer interference. Its product portfolio includes the first-generation AQS³pro MMS instrument, the next-generation Aurora TX automated protein analyzer for biophysical characterization in formulation buffer, the HaLCon real-time protein titer system for bioprocess monitoring, and the delta software package for automated spectral and secondary-structure analysis. Customers use Aurora TX and HaLCon to detect subtle (<2%) structural changes in monoclonal antibodies, antibody-drug conjugates, biosimilars, RNA, peptides, and vaccines, with ~90% non-destructive sample recovery.

The company sells primarily through a direct enterprise field-sales motion with demo-based engagement, supported by an extensive library of application notes, peer-reviewed publications, webinars, and conference participation (e.g., PepTalk, PEGS, BPI Digital). Revenue is generated mainly through capital-equipment sales of Aurora TX and HaLCon instruments to pharmaceutical, biotechnology, CRO/CMO, academic, and government customers, with a smaller recurring component from the integrated delta software platform. Named end users include Pfizer, Amgen, ImmunoGen, Celldex Therapeutics, KBI Biopharma (Elion Labs), the National Institutes for Food and Drug Control of China, and Clark University. The company has raised approximately $71.6 million in disclosed venture funding across nine rounds since 2006, including a $20 million Series E led by Illumina Ventures in October 2021 and follow-on bridge rounds in 2024 and 2025.

RedShift's customer segments are diversified across biopharma R&D, bioprocess manufacturing, contract research/manufacturing, and regulatory/academic use cases, with strategic investors including Illumina Ventures, Waters Corporation, and Technology Venture Partners. The company is led by CEO Julien Bradley and co-founder/CTO Eugene Ma, supported by VPs of engineering and product development. Operating geographies are global rather than US-only, with a documented installation in China's national biologics QC infrastructure.

Short descriptiontext

RedShift BioAnalytics develops and manufactures MMS-based analytical instruments (Aurora TX, HaLCon) that measure protein structure, stability, and titer for biopharmaceutical R&D and bioprocess manufacturing, sold via direct enterprise sales to pharma, biotech, CRO/CMO, academic, and government labs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoxborough, United States
HQ citystring
Boxborough
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
protein analytical instruments, biophysical characterization, bioprocess analytics, biomolecular structure analysis, spectroscopy instrumentation
Industry1 code
PRIMARYHLAGADAK
Material Characterization & Spectroscopy (NMR/FTIR/MS)
NAICS code1 code
  • Analytical Laboratory Instrument Manufacturing334516
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Bioanalytical Instrumentation
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Analytical Instrumentation Sales
TypeHardware Sales
Description

Sale of Aurora TX and HaLCon analytical instruments for protein/biomolecule characterization in biopharmaceutical R&D and manufacturing

redshiftbio.com
2Software/Subscription Services
TypeSubscription Recurring
Description

Delta software for data analysis, integrated into Aurora TX platform for automated protein structural analysis

redshiftbio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Aurora TX
Description

Next-generation fully-automated protein analyzer for biomolecular structure, binding and stability measurement.

redshiftbio.com
+2 more records
Core offering1 text field

RedShift BioAnalytics develops, manufactures, and sells analytical instruments based on its proprietary Microfluidic Modulation Spectroscopy (MMS) technology for protein and biomolecule structural characterization. The product portfolio includes the Aurora TX automated protein analyzer, the HaLCon real-time titer measurement system, and the earlier AQS³pro instrument, supported by the delta software for spectral analysis. These instruments are used by biopharmaceutical R&D and manufacturing teams to detect subtle structural changes in monoclonal antibodies, biosimilars, ADCs, RNA, and vaccines.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

RedShift BioAnalytics offers a portfolio of analytical instruments for protein and biomolecule analysis based on its proprietary Microfluidic Modulation Spectroscopy (MMS) technology. The core product line includes Aurora TX (a next-generation automated protein analyzer for biophysical characterization), HaLCon (a real-time titer measurement system for bioprocess analytics), and the earlier AQS³pro platform. These instruments are supported by the delta software package for automated spectral analysis. The MMS technology uses quantum cascade laser sources and microfluidic flow cells to measure protein secondary structure, stability, aggregation, similarity, and quantitation with high sensitivity across wide concentration ranges without buffer interference.

Product and service4 records
1Aurora TX
CategoryAnalytical Instrumentation
Description

Next-generation automated protein analyzer powered by MMS technology for biopharmaceutical R&D and manufacturing teams. Detects subtle structural changes in biomolecules that impact function and developability, measured directly in formulation buffer. Utilizes quantum cascade laser (QCL) and microfluidic flow cell technology.

2HaLCon
CategoryAnalytical Instrumentation
Description

Automated protein titer measurement system for bioprocessing. Delivers HPLC-level accuracy to guide timely process decisions without offline bottlenecks. Measures protein concentration directly during manufacturing.

3AQS³pro
CategoryAnalytical Instrumentation
Description

First-generation MMS instrument. Novel infrared spectroscopy tool that measures protein secondary structure in a non-destructive manner, enabling subsequent characterization and analysis with approximately 90% sample recovery.

4delta Software
CategoryAnalytical Software
Description

Integrated software package for the Aurora TX platform that performs automated spectral analysis and second derivative processing to elucidate protein structural composition. Includes a built-in protein library and is used for higher-order structure (HOS) analysis and structural population monitoring.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Unchained Labs develops protein analytical instruments (e.g., Uncle, Stunner, Freeslate) for biologics formulation, stability, and biophysical characterization. It directly competes with RedShift in protein therapeutic analytics targeting similar biopharma R&D and formulation customers.

TypeDirect peer
Description

Waters is a global leader in liquid chromatography and mass spectrometry for protein characterization, and owns Wyatt Technology (light scattering for macromolecules). Waters is also a strategic investor in RedShift across two funding rounds, making it both a peer and a partner.

TypeBroad incumbent
Description

Bruker is a broad analytical instrumentation incumbent offering NMR, FTIR, mass spectrometry, and biophysical characterization tools used in protein therapeutics R&D. While not specifically QCL-microfluidic, its spectroscopy portfolio overlaps with MMS use cases in structural biology.

TypeDirect peer
Description

Repligen provides bioprocess analytics and chromatography solutions for biologics manufacturing. Its at-line and online PAT offerings compete directly with HaLCon in real-time bioprocess titer and protein monitoring for CDMOs and biopharma manufacturers.

TypeBroad incumbent
Description

Cytiva offers a broad bioprocessing portfolio including ÄKTA systems, sensors, and PAT tools for biologics manufacturing. Its bioprocess analytics suite overlaps with RedShift's HaLCon use case in CDMO and biopharma manufacturing settings.

TypeBroad incumbent
Description

Agilent manufactures analytical instruments including FTIR, UV-Vis, and biopharma LC/MS solutions used in protein characterization. Its broad spectroscopy and chromatography portfolio competes indirectly with MMS across structural biology workflows.

TypeBroad incumbent
Description

Thermo Fisher provides a comprehensive analytical instrument portfolio including FTIR (Nicolet), CD spectroscopy, and biopharma-focused tools. It is a deep incumbent across nearly every workflow where MMS competes, with vastly greater sales and service reach.

TypeBroad incumbent
Description

Sartorius offers bioprocess solutions including sensors and PAT analytics for upstream and downstream bioprocessing. Its IncPAT platform overlaps with HaLCon's positioning in real-time bioprocess monitoring for biologics manufacturing.

TypeDirect peer
Description

Applied Photophysics specializes in Circular Dichroism (CD) spectrometers for protein secondary structure and stability analysis. Its Chirascan platform is one of the legacy techniques (alongside FTIR) that MMS is designed to displace or complement in biopharma workflows.

TypeEmerging player
Description

Fluidic Analytics develops microfluidic-based protein interaction analysis tools (Fluidity One) targeting similar protein characterization use cases. Its microfluidic platform intersects with RedShift's MMS microfluidic flow cell approach, but focuses on interaction/sizing rather than secondary structure.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RedShift BioAnalytics

Bioanalytical Instrumentationredshiftbio.com

RedShift BioAnalytics develops and manufactures MMS-based analytical instruments (Aurora TX, HaLCon) that measure protein structure, stability, and titer for biopharmaceutical R&D and bioprocess manufacturing, sold via direct enterprise sales to pharma, biotech, CRO/CMO, academic, and government labs.

What RedShift BioAnalytics does

RedShift BioAnalytics, Inc. (operating as RedShiftBio) is a privately held, Delaware-incorporated analytical instrumentation company founded in 2005 and headquartered at 80 Central Street, Boxborough, Massachusetts. It develops and manufactures bioanalytical tools based on its proprietary Microfluidic Modulation Spectroscopy (MMS) platform, which pairs a tunable quantum cascade laser (at least ~1,000x more intense than conventional IR sources) with a microfluidic flow cell to enable real-time background subtraction and ultra-sensitive measurement of protein secondary structure across a 0.1 to >200 mg/mL concentration range with minimal buffer interference. Its product portfolio includes the first-generation AQS³pro MMS instrument, the next-generation Aurora TX automated protein analyzer for biophysical characterization in formulation buffer, the HaLCon real-time protein titer system for bioprocess monitoring, and the delta software package for automated spectral and secondary-structure analysis. Customers use Aurora TX and HaLCon to detect subtle (<2%) structural changes in monoclonal antibodies, antibody-drug conjugates, biosimilars, RNA, peptides, and vaccines, with ~90% non-destructive sample recovery.

The company sells primarily through a direct enterprise field-sales motion with demo-based engagement, supported by an extensive library of application notes, peer-reviewed publications, webinars, and conference participation (e.g., PepTalk, PEGS, BPI Digital). Revenue is generated mainly through capital-equipment sales of Aurora TX and HaLCon instruments to pharmaceutical, biotechnology, CRO/CMO, academic, and government customers, with a smaller recurring component from the integrated delta software platform. Named end users include Pfizer, Amgen, ImmunoGen, Celldex Therapeutics, KBI Biopharma (Elion Labs), the National Institutes for Food and Drug Control of China, and Clark University. The company has raised approximately $71.6 million in disclosed venture funding across nine rounds since 2006, including a $20 million Series E led by Illumina Ventures in October 2021 and follow-on bridge rounds in 2024 and 2025.

RedShift's customer segments are diversified across biopharma R&D, bioprocess manufacturing, contract research/manufacturing, and regulatory/academic use cases, with strategic investors including Illumina Ventures, Waters Corporation, and Technology Venture Partners. The company is led by CEO Julien Bradley and co-founder/CTO Eugene Ma, supported by VPs of engineering and product development. Operating geographies are global rather than US-only, with a documented installation in China's national biologics QC infrastructure.

RedShift BioAnalytics firmographics

Firmographics
Name
RedShift BioAnalytics
Legal name
RedShift BioAnalytics, Inc.
Website
https://redshiftbio.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
11–50 employees
Short description
RedShift BioAnalytics develops and manufactures MMS-based analytical instruments (Aurora TX, HaLCon) that measure protein structure, stability, and titer for biopharmaceutical R&D and bioprocess manufacturing, sold via direct enterprise sales to pharma, biotech, CRO/CMO, academic, and government labs.
Ownership category
akta.pro rank

RedShift BioAnalytics industry classification

Industry
Product category
Bioanalytical Instrumentation
NAICS
Analytical Laboratory Instrument Manufacturing (334516)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGADAK
Material Characterization & Spectroscopy (NMR/FTIR/MS)

Keywords

  • Protein analytical instruments
  • Biophysical characterization
  • Bioprocess analytics
  • Biomolecular structure analysis
  • Spectroscopy instrumentation

Where RedShift BioAnalytics is headquartered

Location

Headquarters

HQ city
Boxborough
HQ country
United States
HQ region
North America

Offices1 record

Markets served

RedShift BioAnalytics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

  1. Analytical Instrumentation Sales: Sale of Aurora TX and HaLCon analytical instruments for protein/biomolecule characterization in biopharmaceutical R&D and manufacturing
  2. Software/Subscription Services: Delta software for data analysis, integrated into Aurora TX platform for automated protein structural analysis

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

RedShift BioAnalytics product offering

Product offering

Core offering

RedShift BioAnalytics develops, manufactures, and sells analytical instruments based on its proprietary Microfluidic Modulation Spectroscopy (MMS) technology for protein and biomolecule structural characterization. The product portfolio includes the Aurora TX automated protein analyzer, the HaLCon real-time titer measurement system, and the earlier AQS³pro instrument, supported by the delta software for spectral analysis. These instruments are used by biopharmaceutical R&D and manufacturing teams to detect subtle structural changes in monoclonal antibodies, biosimilars, ADCs, RNA, and vaccines.

Product overview

RedShift BioAnalytics offers a portfolio of analytical instruments for protein and biomolecule analysis based on its proprietary Microfluidic Modulation Spectroscopy (MMS) technology. The core product line includes Aurora TX (a next-generation automated protein analyzer for biophysical characterization), HaLCon (a real-time titer measurement system for bioprocess analytics), and the earlier AQS³pro platform. These instruments are supported by the delta software package for automated spectral analysis. The MMS technology uses quantum cascade laser sources and microfluidic flow cells to measure protein secondary structure, stability, aggregation, similarity, and quantitation with high sensitivity across wide concentration ranges without buffer interference.

Differentiator

Problem solved

Functional benefit

Brands

  • Aurora TX: Next-generation fully-automated protein analyzer for biomolecular structure, binding and stability measurement.
  • HaLCon
  • AQS³pro

Products and services

  • Aurora TX Next-generation automated protein analyzer powered by MMS technology for biopharmaceutical R&D and manufacturing teams. Detects subtle structural changes in biomolecules that impact function and developability, measured directly in formulation buffer. Utilizes quantum cascade laser (QCL) and microfluidic flow cell technology.
  • HaLCon Automated protein titer measurement system for bioprocessing. Delivers HPLC-level accuracy to guide timely process decisions without offline bottlenecks. Measures protein concentration directly during manufacturing.
  • AQS³pro First-generation MMS instrument. Novel infrared spectroscopy tool that measures protein secondary structure in a non-destructive manner, enabling subsequent characterization and analysis with approximately 90% sample recovery.
  • delta Software Integrated software package for the Aurora TX platform that performs automated spectral analysis and second derivative processing to elucidate protein structural composition. Includes a built-in protein library and is used for higher-order structure (HOS) analysis and structural population monitoring.

Companies that use RedShift BioAnalytics

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles4 records

RedShift BioAnalytics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

RedShift BioAnalytics partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

RedShift BioAnalytics competitors and assessment

Company assessment

Direct peers

  • Unchained Labs: Unchained Labs develops protein analytical instruments (e.g., Uncle, Stunner, Freeslate) for biologics formulation, stability, and biophysical characterization. It directly competes with RedShift in protein therapeutic analytics targeting similar biopharma R&D and formulation customers.
  • Waters Corporation: Waters is a global leader in liquid chromatography and mass spectrometry for protein characterization, and owns Wyatt Technology (light scattering for macromolecules). Waters is also a strategic investor in RedShift across two funding rounds, making it both a peer and a partner.
  • Repligen Corporation: Repligen provides bioprocess analytics and chromatography solutions for biologics manufacturing. Its at-line and online PAT offerings compete directly with HaLCon in real-time bioprocess titer and protein monitoring for CDMOs and biopharma manufacturers.
  • Applied Photophysics: Applied Photophysics specializes in Circular Dichroism (CD) spectrometers for protein secondary structure and stability analysis. Its Chirascan platform is one of the legacy techniques (alongside FTIR) that MMS is designed to displace or complement in biopharma workflows.

Broad incumbents

  • Bruker Corporation: Bruker is a broad analytical instrumentation incumbent offering NMR, FTIR, mass spectrometry, and biophysical characterization tools used in protein therapeutics R&D. While not specifically QCL-microfluidic, its spectroscopy portfolio overlaps with MMS use cases in structural biology.
  • Cytiva (Danaher): Cytiva offers a broad bioprocessing portfolio including ÄKTA systems, sensors, and PAT tools for biologics manufacturing. Its bioprocess analytics suite overlaps with RedShift's HaLCon use case in CDMO and biopharma manufacturing settings.
  • Agilent Technologies: Agilent manufactures analytical instruments including FTIR, UV-Vis, and biopharma LC/MS solutions used in protein characterization. Its broad spectroscopy and chromatography portfolio competes indirectly with MMS across structural biology workflows.
  • Thermo Fisher Scientific: Thermo Fisher provides a comprehensive analytical instrument portfolio including FTIR (Nicolet), CD spectroscopy, and biopharma-focused tools. It is a deep incumbent across nearly every workflow where MMS competes, with vastly greater sales and service reach.
  • Sartorius AG: Sartorius offers bioprocess solutions including sensors and PAT analytics for upstream and downstream bioprocessing. Its IncPAT platform overlaps with HaLCon's positioning in real-time bioprocess monitoring for biologics manufacturing.

Emerging players

  • Fluidic Analytics: Fluidic Analytics develops microfluidic-based protein interaction analysis tools (Fluidity One) targeting similar protein characterization use cases. Its microfluidic platform intersects with RedShift's MMS microfluidic flow cell approach, but focuses on interaction/sizing rather than secondary structure.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

RedShift BioAnalytics social profiles

Digital presence

RedShift BioAnalytics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RedShift BioAnalytics leadership team

Management profile

Number of profiles

Profiles4 records

RedShift BioAnalytics funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RedShift BioAnalytics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RedShift BioAnalytics

What does RedShift BioAnalytics do?

RedShift BioAnalytics develops, manufactures, and sells analytical instruments based on its proprietary Microfluidic Modulation Spectroscopy (MMS) technology for protein and biomolecule structural characterization. The product portfolio includes the Aurora TX automated protein analyzer, the HaLCon real-time titer measurement system, and the earlier AQS³pro instrument, supported by the delta software for spectral analysis. These instruments are used by biopharmaceutical R&D and manufacturing teams to detect subtle structural changes in monoclonal antibodies, biosimilars, ADCs, RNA, and vaccines.

Is RedShift BioAnalytics a public or private company?

RedShift BioAnalytics is a private company. It is classified as venture growth investor backed and is currently operating.

When was RedShift BioAnalytics founded?

RedShift BioAnalytics was founded in 2005. It employs 11 to 50 people.

Where is RedShift BioAnalytics based?

RedShift BioAnalytics is headquartered in Boxborough, United States, in the North America region.

How does RedShift BioAnalytics make money?

Two revenue lines are on record. Analytical Instrumentation Sales are the primary driver. The others are software/Subscription Services.

Who are RedShift BioAnalytics's main competitors?

Direct peers on record are Unchained Labs, Waters Corporation, Repligen Corporation and Applied Photophysics. Broad incumbents are Bruker Corporation, Cytiva (Danaher), Agilent Technologies, Thermo Fisher Scientific and Sartorius AG. Fluidic Analytics is listed as an emerging player.

Does RedShift BioAnalytics have an API?

No public API is recorded for RedShift BioAnalytics.

What industry is RedShift BioAnalytics in?

RedShift BioAnalytics's product category is Bioanalytical Instrumentation. Its primary akta.pro industry code is HLAGADAK, Material Characterization & Spectroscopy (NMR/FTIR/MS). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireRedShiftBio Launches Aurora TX: Revolutionizing RNA and Protein Analysis with Ultra-Sensitive Microfluidic Modulation Spectroscopy and Thermal Ramping CapabilityRedShiftBio launched the Aurora TX instrument, a biophysical characterization system utilizing Microfluidic Modulation Spectroscopy (MMS) with thermal ramping capabilities, at The Protein & Antibody Engineering Summit in Boston. This new device enables ultra-sensitive analysis of RNA, proteins, and other biomolecules, addressing limitations of existing technologies like CD and FTIR. The launch aims to accelerate biopharmaceutical drug development by providing researchers with automated, high-precision structural stability data.SecSEC FORM DRedShift BioAnalytics, Inc. filed a Form D with the SEC on April 2, 2024, announcing an exempt securities offering under Rule 506(b) with a total target amount of $7 million. The company has already sold $5 million in equity securities to six investors since the first sale date of March 21, 2024.BioSpaceRedShift BioAnalytics Announces Distribution Agreement with Flownamics for The Director™ Liquid Handler.RedShift BioAnalytics signed a global distribution agreement with Flownamics for the Director Sample Distribution System, effective immediately. The system automates sample handling for the HaLCon Analyzer, enabling real-time protein titer measurements in minutes. The Director is available for shipment in North America, Europe, and Asia.PR NewswireRedShift BioAnalytics Announces Distribution Agreement with Flownamics for The Director™ Liquid Handler.RedShift BioAnalytics has signed a global distribution agreement with Flownamics to sell the Director Sample Distribution System, a liquid handler optimized for bioprocessing and cell line development. The agreement enables RedShiftBio to offer integrated walkaway automation combining the Director with its HaLCon Analyzer, which provides real-time protein titer measurements in under five minutes. The partnership is effective immediately with availability in North America, Europe, and Asia, allowing biopharmaceutical companies to obtain accurate titer measurements from bioreactor samples faster than traditional HPLC methods.PR NewswireRedShift BioAnalytics Launches HaLCon™ Analyzer, Providing Simple and Accurate On-Demand Protein Titer Measurements for Bioprocess Development and ManufacturingRedShift BioAnalytics launched the HaLCon Analyzer, a liquid chromatography system designed to provide rapid and accurate protein titer measurements for biopharmaceutical development. The device enables users without advanced training to obtain results in under five minutes at the point of need, offering a cost-effective alternative to traditional HPLC methods. RedShiftBio is making the analyzer available for immediate shipment across North America, Europe, and Asia.SecSEC FORM DRedShift BioAnalytics, Inc. filed a Form D with the SEC to report an exempt offering of securities under Rule 506(b), with a total offering amount of approximately $20 million. The filing indicates that nearly $10 million has already been sold to 12 investors as of October 15, 2021, with sales conducted through Bowen Advisors Inc.BioSpaceRedShift BioAnalytics Closes $20M Series E Funding Led by Illumina VenturesRedShift BioAnalytics closed a $20 million Series E financing led by Illumina Ventures, with participation from Technology Venture Partners and Waters Corporation. The company will use the proceeds for commercial expansion, technology innovation, and product development. The financing validates its Microfluidic Modulation Spectroscopy platform and supports growth in structural biology.RedshiftbioRedShiftBio Secures $20M Series E FundingRedShiftBioAnalytics closed a $20 million Series E financing round led by Illumina Ventures, with participation from existing investors Technology Venture Partners and Waters Corporation. The company intends to use the proceeds to support commercial expansion, technology innovation, and product development objectives.BioSpaceRedShift BioAnalytics Appoints Amol Chaubal, CFO of Waters Corporation, to Board of DirectorsRedShift BioAnalytics appointed Amol Chaubal, CFO of Waters Corporation, to its Board of Directors. Chaubal previously served as CFO at Quanterix and Smith & Nephew. The appointment aims to support the company's growth in biopharmaceuticals.